RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
RSK3/4 mediate resistance to PI3K pathway inhibitors in breast cancer
Authors
Keywords
-
Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 123, Issue 6, Pages 2551-2563
Publisher
American Society for Clinical Investigation
Online
2013-04-30
DOI
10.1172/jci66343
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinical combination of the MEK inhibitor GDC-0973 and the PI3K inhibitor GDC-0941: A first-in-human phase Ib study testing daily and intermittent dosing schedules in patients with advanced solid tumors.
- (2017) G. Shapiro et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting RSK: An Overview of Small Molecule Inhibitors
- (2012) Tam Nguyen Anti-Cancer Agents in Medicinal Chemistry
- Abstract CT-01: BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study
- (2012) D. Juric et al. CANCER RESEARCH
- The Clinical Effect of the Dual-Targeting Strategy Involving PI3K/AKT/mTOR and RAS/MEK/ERK Pathways in Patients with Advanced Cancer
- (2012) T. Shimizu et al. CLINICAL CANCER RESEARCH
- PI3K/AKT/mTOR Inhibitors in Patients With Breast and Gynecologic Malignancies HarboringPIK3CAMutations
- (2012) Filip Janku et al. JOURNAL OF CLINICAL ONCOLOGY
- Molecular Profiling of Patients with Colorectal Cancer and Matched Targeted Therapy in Phase I Clinical Trials
- (2012) R. Dienstmann et al. MOLECULAR CANCER THERAPEUTICS
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- β-catenin confers resistance to PI3K and AKT inhibitors and subverts FOXO3a to promote metastasis in colon cancer
- (2012) Stephan P Tenbaum et al. NATURE MEDICINE
- KRASness and PIK3CAness in Patients with Advanced Colorectal Cancer: Outcome after Treatment with Early-Phase Trials with Targeted Pathway Inhibitors
- (2012) Ignacio Garrido-Laguna et al. PLoS One
- PI3K Inhibition Impairs BRCA1/2 Expression and Sensitizes BRCA-Proficient Triple-Negative Breast Cancer to PARP Inhibition
- (2012) Yasir H. Ibrahim et al. Cancer Discovery
- Regulation and function of the RSK family of protein kinases
- (2011) Yves Romeo et al. BIOCHEMICAL JOURNAL
- AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity
- (2011) Sarat Chandarlapaty et al. CANCER CELL
- RSK4 inhibition results in bypass of stress-induced and oncogene-induced senescence
- (2011) L. Lopez-Vicente et al. CARCINOGENESIS
- PRKX, TTBK2 and RSK4 expression causes sunitinib resistance in kidney carcinoma- and melanoma-cell lines
- (2011) Claus Bender et al. INTERNATIONAL JOURNAL OF CANCER
- Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors
- (2011) Johanna C. Bendell et al. JOURNAL OF CLINICAL ONCOLOGY
- Targeting cap-dependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma
- (2011) Jonathan H. Schatz et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Identification and Characterization of NVP-BKM120, an Orally Available Pan-Class I PI3-Kinase Inhibitor
- (2011) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- PIK3CA Mutations in Patients with Advanced Cancers Treated with PI3K/AKT/mTOR Axis Inhibitors
- (2011) F. Janku et al. MOLECULAR CANCER THERAPEUTICS
- A chemical-genetic screen reveals a mechanism of resistance to PI3K inhibitors in cancer
- (2011) Markus K Muellner et al. Nature Chemical Biology
- Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway–dependent and PI3K pathway–independent mechanisms
- (2011) Pixu Liu et al. NATURE MEDICINE
- A public genome-scale lentiviral expression library of human ORFs
- (2011) Xiaoping Yang et al. NATURE METHODS
- Towards systematic functional characterization of cancer genomes
- (2011) Jesse S. Boehm et al. NATURE REVIEWS GENETICS
- Everolimus for Advanced Pancreatic Neuroendocrine Tumors
- (2011) James C. Yao et al. NEW ENGLAND JOURNAL OF MEDICINE
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer
- (2011) José Baselga et al. NEW ENGLAND JOURNAL OF MEDICINE
- PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs
- (2011) B Weigelt et al. ONCOGENE
- PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
- (2011) V Serra et al. ONCOGENE
- PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis
- (2011) N. Ilic et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Predictive Biomarkers of Sensitivity to the Phosphatidylinositol 3' Kinase Inhibitor GDC-0941 in Breast Cancer Preclinical Models
- (2010) C. O'Brien et al. CLINICAL CANCER RESEARCH
- A genome-wide RNAi screen identifies multiple RSK-dependent regulators of cell migration
- (2010) G. A. Smolen et al. GENES & DEVELOPMENT
- Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus
- (2010) Federica Di Nicolantonio et al. JOURNAL OF CLINICAL INVESTIGATION
- RSK-Mediated Phosphorylation in the C/EBPβ Leucine Zipper Regulates DNA Binding, Dimerization, and Growth Arrest Activity
- (2010) Sook Lee et al. MOLECULAR AND CELLULAR BIOLOGY
- Regulation of the mTOR Complex 1 Pathway by Nutrients, Growth Factors, and Stress
- (2010) Shomit Sengupta et al. MOLECULAR CELL
- COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
- (2010) Cory M. Johannessen et al. NATURE
- Towards a knowledge-based Human Protein Atlas
- (2010) Mathias Uhlen et al. NATURE BIOTECHNOLOGY
- Development of a mouse model for sporadic and metastatic colon tumors and its use in assessing drug treatment
- (2010) K. E. Hung et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- A Technical Assessment of the Utility of Reverse Phase Protein Arrays for the Study of the Functional Proteome in Non-microdissected Human Breast Cancers
- (2010) Bryan T. Hennessy et al. Clinical Proteomics
- Regulation of Replicative and Stress-Induced Senescence by RSK4, which is Down-regulated in Human Tumors
- (2009) L. Lopez-Vicente et al. CLINICAL CANCER RESEARCH
- In vivo Antitumor Activity of MEK and Phosphatidylinositol 3-Kinase Inhibitors in Basal-Like Breast Cancer Models
- (2009) K. P. Hoeflich et al. CLINICAL CANCER RESEARCH
- PI3K and mTOR inhibitors—a new generation of targeted anticancer agents
- (2009) Saskia Brachmann et al. CURRENT OPINION IN CELL BIOLOGY
- Targeting the PI3K signaling pathway in cancer
- (2009) Kwok-Kin Wong et al. CURRENT OPINION IN GENETICS & DEVELOPMENT
- Targeting the phosphoinositide 3-kinase pathway in cancer
- (2009) Pixu Liu et al. NATURE REVIEWS DRUG DISCOVERY
- Specific apoptosis induction by the dual PI3K/mTor inhibitor NVP-BEZ235 in HER2 amplified and PIK3CA mutant breast cancer cells
- (2009) Saskia M. Brachmann et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
- (2009) Morris E Feldman et al. PLOS BIOLOGY
- NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations
- (2008) V. Serra et al. CANCER RESEARCH
- Phosphatidylinositol 3-Kinase Hyperactivation Results in Lapatinib Resistance that Is Reversed by the mTOR/Phosphatidylinositol 3-Kinase Inhibitor NVP-BEZ235
- (2008) P. J.A. Eichhorn et al. CANCER RESEARCH
- Anti-invasive and Antimetastatic Activities of Ribosomal Protein S6 Kinase 4 in Breast Cancer Cells
- (2008) A. Thakur et al. CLINICAL CANCER RESEARCH
- Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial
- (2008) Robert J Motzer et al. LANCET
- Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
- (2008) S.-M. Maira et al. MOLECULAR CANCER THERAPEUTICS
- Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
- (2008) Jeffrey A Engelman et al. NATURE MEDICINE
- The RSK family of kinases: emerging roles in cellular signalling
- (2008) Rana Anjum et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now